Drugs / TV48108
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02315144 | Apr → Aug 2015 | chronic obstructive pulmonary disease | Teva Branded Pharmaceutical Products R&D, Inc. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TV48108 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02315144 ↗ |
| Route | Inhaled | “single inhaled dose of TV48108 120 µg” NCT02315144 ↗ |